Organization
University Hospital 12 de Octubre
34 abstracts
3 posters
Abstract
Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.Org: Medical Department, Oncology Therapeutic Development, Charité Universitätsmedizin Berlin, Comprehensive Cancer Center at Ludwig Maximilian University of Munich, MVZ Gesundheitszentrum St. Marien GmbH,
Abstract
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.Org: Agomab Spain, LMU Munich, The Jikei University School of Medicine, Co-ordinating Center for Clinical Trials of the Philipps-University of Marburg, Seoul National University Hospital,
Abstract
Cyclin E cytoplasmatic isoform to predict outcome and benefit to capecitabine treatment in patients with HR+/HER2- metastatic breast cancer from the GEICAM/2013-02 PEARL study.Org: Instituto Valenciano de Oncología, Institut Català d'Oncologia (ICO) & IDIBELL, Medical University Vienna, Central European Cooperative Oncology Group, Medical Oncology Department,
Abstract
Early prediction of endocrine responsiveness in ER+/HER2 negative MBC: Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.Org: EO Ospedali Galliera, University Hospital Munich, International Breast Cancer Center (IBCC), Vall d'Hebron Institute of Oncology, Maggiore della Carità University Hospital,
Abstract
Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).Org: University of Bielefeld, Medical University of Graz, Department of Radiation Oncology, University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany,
Abstract
Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).Org: Centre Hospitalier Universitaire de Nantes, Ankara University, University of Athens, School of Medicine, Showa University, Memorial Sloan Kettering Cancer Center,
Abstract
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.Org: University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), Swiss Group for Clinical Cancer Research (SAKK), Department of Internal Medicine III with Hematology,
Abstract
Real-world treatment outcomes in patients with HR+ HER2- advanced breast cancer treated with CDK4/6 inhibitors and endocrine therapy.Org: Military Institute of Medicine-National Research Institute, Department of Oncology, National Taiwan University Hospital, Department of Clinical Oncology, Queen Elizabeth Hospital, Breast Unit, Lower Silesian Oncology Centre,
Abstract
Barriers to accrual and enrollment in brain tumor trials.Org: Dana-Farber Cancer Institute, Massachusetts General Hospital, University of California Irvine, The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center School of Nursing,
Abstract
Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.Org: GEICO, Arcagy-Gineco, NSGO-CTU, SAKK, BGOG,
Abstract
Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).Org: Université de Poitiers et Centre Hospitalier Universitaire de Poitiers, INSERM U1313 and CIC 1082, Poitiers, France, Hôpital Haut Leveque, University Hospital, Pessac, France, ECSTRA, Centre de Recherche en Epidémiologie et Statistiques, INSERM UMR 1153, Paris, France, Lille University Hospital, Lille, France, CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France,
Abstract
A new prognostic tool for metastatic colorectal cancer patients receiving anti-angiogenic treatment, the PALM score: A single-center experience.Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, University Hospital 12 de Octubre, University of Cagliari, Medical Oncolgy Unit,
Abstract
Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).Org: Erasmus MC Cancer Center, Rotterdam, Netherlands Cancer Institute, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Fondazione IRCCS Istituto Neurologico Carlo Besta,
Abstract
15-month safety and efficacy data after intraperitoneal treatment with 224Radium-labelled microparticles after CRS-HIPEC for peritoneal metastasis from colorectal cancer.Org: Norwegian Radium Hospital, Department of Surgical Sciences, Uppsala University and Akademiska sjukhuset-Blod-och tumorsjukdomar, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway, University Hospital 12 de Octubre,
Abstract
Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAF V600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment.Org: University of Pisa, Pisa, Italy, Azienda Ospedaliero-Universitaria Pisana, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Veneto Institute of Oncology IOV - IRCCS,
Abstract
Optimal molecular-targeted therapies as first-line treatment for RAS wild-type, right-sided metastatic colorectal cancer from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.Org: Shizuoka Cancer Center, Nagaizumi, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Kyushu University, University of Nantes Medical School Nantes, University Medical Center Utrecht,
Abstract
Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial.Org: University Hospital 12 de Octubre, Perth Oncology, Western Health,
Abstract
Comprehensive nationwide study on the prescription of experimental anticancer therapies for compassionate use in children and adolescents in France.Org: Gustave Roussy Cancer Campus, French National Authority for Health, Institut Curie, Saint Cloud, France, IHOPe-CLB, Paediatric Haematology-Oncology Department,
Abstract
Onco-PDO test utilizing patient-derived organoids (PDOs) and next-generation precision oncology in breast cancer.Org: Invitrocue Europe AG, Invitrocue Hong Kong Ltd, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, Technical University of Munich (TUM), Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China,
Abstract
Influence of modified Lugano criteria by pre-infusion tumor kinetics on early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy.Org: LMU Munich, University Hospital LMU Munich, Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich, University Hospital 12 de Octubre, Ludwig Maximilians University of Munich,
Abstract
Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, University Hospital 12 de Octubre, LMU Munich, Munich, Germany, Germany,
Abstract
Influence of levothyroxine concomitant treatment on treatment responses and outcomes in patients with metastatic colorectal adenocarcinoma.Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, University Hospital 12 de Octubre, University of Cagliari, Medical Oncolgy Unit,
Abstract
Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity.Org: EHC, Morges, Switzerland, University Hospital 12 de Octubre, Institut Curie, Saint Cloud, France, Centre GF Leclercq,
Abstract
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.Org: Hôpital Européen Georges-Pompidou, Paris, Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, University Hospital 12 de Octubre, LMU Munich,
Abstract
Incidence of metachronous peritoneal metastases for intrahepatic cholangiocarcinoma after curative resection: A single center cohort analysis.Org: Charité - Universitätsmedizin Berlin, Berlin, Germany, Chirurgische Klinik, Charité– Universitaetsmedizin Berlin, Medizinische Hochschule Hannover, Charite-Universitätsmedizin Berlin, Department of Gynecology with Center for Oncological Surgery, Campus Virchow Klinikum, Berlin, Germany,
Abstract
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients.Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, University Hospital 12 de Octubre, University of Cagliari, University Hospital St Raphael, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,
Abstract
99M TECHNETIUM-PYROPHOSPHATE SCINTIGRAPHY IN THE DIAGNOSIS OF INFLAMMATORY MUSCLE DISEASEOrg: Internal Medicine II, Nuclear Medicine and PET Center Department, University Hospital 12 de Octubre, Tübingen University Hospital, Germany,
Abstract
AUTOANTIBODIES - PREDICTORS OF AGGRESSIVE RHEUMATOID ARTHRITISOrg: Clinic of Rheumatology, University of Lübeck, Lübeck, University Hospital 12 de Octubre, Laboratory of Microbiology and Immunology, University Hospital "St. George", Plovdiv, Bulgaria,
Abstract
A NEURAL NETWORK BASED CLUSTERING MODEL OF A COLOMBIAN COHORT OF RHEUMATOID ARTHRITIS PATIENTSOrg: University Hospital 12 de Octubre, School of Engineering Medicine，Beihang University, LISI research group, Reumavance research group, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
A HISTORY OF RECENT CLINICAL FRACTURE IS A STRONGER RISK FACTOR THAN LOW BMD IN PREDICTING 5-YEAR INCIDENCE OF CLINICAL FRACTURESOrg: Rheumatology, University Hospital 12 de Octubre, General Practice, Statistics Division, University of California Irvine,
Abstract
A double blind, randomized trial of the gastrointestinal safety and efficacy of pentahydrate calcique indometacin compared with diclofenac in patients with osteoarthritis of the kneeOrg: Rheumatology, Epidemiology and Biostatistics, El Ayachi hospital, Salé, university military hospital,
Abstract
ANTI-CCP ANTIBODIES AND IGA-RHEUMATOID FACTOR PREDICT THE DEVELOPMENT OF RHEUMATOID ARTHRITISOrg: University Hospital 12 de Octubre, Biochemistry, University of Kiel, Kiel, Germany, University of Nijmegen, Nutritional Research, Virology, University Teaching Hospital, Besancon, France,
Abstract
ALTERED REGULATION OF METABOLIC PATHWAYS IN OSTEOARTHRITIS EVIDENCED BY METABOLOMICS Org: Rheumatology, Society of Patients with Rheumatism, Cracow, Poland, University Hospital 12 de Octubre, UMR 7177, University, Strasbourg, France,
Abstract
BEHCET''S DISEASE: LONG TERM VISUAL PROGNOSIS AFTER TREATMENT WITH INTERFERON-ALPHA2AOrg: Internal Medicine II, Ophthalmology, Hospital Universitario La Fe, Valencia, University Hospital 12 de Octubre, Tuebingen University Hospital, Germany,